Merck-Eisai endometrial cancer therapy combo fails first-line treatment trial

The combination is already approved in the U.S. and other countries to treat certain types of advanced endometrial cancer in patients who have received prior systemic therapy.

In the current study, the Keytruda-Lenvima combination failed to delay the progression of the cancer and prolong the lives of patients with a type of advanced or recurrent endometrial cancer.

The cancer begins in the inner lining of the uterus, or endometrium, and is the most common type of the disease affecting the organ.

Friday's data does not affect the approved indications for the combination or other ongoing trials, Merck said.

Merck's Keytruda belongs to a class of medicines called PD-1 inhibitors that work by increasing the ability of the body's immune system to detect and fight tumor cells.

Eisai's Lenvima is a kinase inhibitor, which blocks certain proteins from helping cancer cells grow and divide.

Lenvima brought in global sales of 151.4 billion yen ($1.05 billion) for the six months ended Sept. 30.